Trial Profile
A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Pegtibatinase (Primary)
- Indications Homocystinuria
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Acronyms COMPOSE
- Sponsors Travere Therapeutics
- 04 Apr 2024 According to a Travere Therapeutics media release, data from the study will be presented at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.
- 15 Feb 2024 According to a Travere Therapeutics media release, company will be initiating this ENSEMBLE Study of pegtibatinase in participants with HCU following their completion of the Phase 1/2 COMPOSE Study or the HARMONY Study.
- 11 Jan 2024 Planned End Date changed from 1 Jun 2025 to 1 Dec 2026.